Gastric Cancer Roundtables
Advertisement
The panel concludes with a discussion on treatment strategies for metastatic esophageal squamous cell carcinoma.
The panel shifts focus to the 1L treatment of metastatic gastroesophageal cancers, exploring biomarker testing strategies.
The panel delves into the implications of recent data on IO in the perioperative, adjuvant treatment of upper GI cancers.
The panel takes a deep dive into the evolving role of IO in resectable GE cancer, with a focus on the results of MATTERHORN.
The panel launches into a discussion of practice-changing data, focusing on MATTERHORN and its impact on disease management.
The panel discusses considerations around treating peritoneal gastric cancer, including the role of HIPEC.
In part three of their discussion, the panel explores the role of ADCs in treating gastric and esophageal cancers.
The panelists discuss the impact of biomarkers on personalized gastric cancer care, including ctDNA, claudin 18.2, and PD-L1.
An expert panel of GI oncologists debates recent advancements in biomarker-driven strategies for GI cancer care.
The panel covers ASPEN-O6 results, excitement around ADCs in late-line HER-2 and Claudin-positive cancers, and more.
The panel considers tislelizumab amid existing PD-1 inhibitors, zolbetuximab for Claudin-positive patients, and more.
The panel covers updates on 1L treatments for metastatic gastric cancer, including the recent approval of tislelizumab.
The panel explores advancements in early-stage esophageal cancer, emphasizing the paradigm shift toward FLOT chemotherapy.
Personalized Care in Gastric and Esophageal Cancers: Biomarkers, Diagnosis, and Treatment Approaches
The panel focuses on the management of gastroesophageal cancers, highlighting differences in presentations across regions.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.